- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04556773
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Study Overview
Status
Conditions
Detailed Description
This study is modular in design allowing assessment of the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies. Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose expansion phase (Part 2); the Part 2 dose-expansion phase will use the RP2D determined in Part 1.
The target population of interest in this study is patients with HER2-low (IHC 1+ or IHC 2+/ISH -) (as per ASCO/CAP 2018 guidelines) advanced/MBC. Part 1 of each module will enroll patients with locally confirmed HER2-low advanced/MBC in second-line or later (≥ 2L) settings
Part 2 of each module will enroll patients with HER2-low MBC who have either not received prior treatment, or received only 1 prior treatment (depending on the module-specific exclusion criteria) for advanced/metastatic disease
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
East Melbourne, Australia, 3002
- Research Site
-
Westmead, Australia, 2145
- Research Site
-
-
-
-
-
Edegem, Belgium, 2650
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Ottignies, Belgium, 1340
- Research Site
-
-
-
-
-
Goiania, Brazil, 74605-070
- Research Site
-
Porto Alegre, Brazil, 90035-003
- Research Site
-
Porto Alegre, Brazil, 90110-270
- Research Site
-
Sao Paulo, Brazil, 04543-000
- Research Site
-
São Paulo, Brazil, 03102-002
- Research Site
-
-
-
-
-
Quebec, Canada, G1J 1Z4
- Research Site
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Research Site
-
-
-
-
-
Villejuif Cedex, France, 94805
- Research Site
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 03080
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
-
-
-
-
Monterrey, Mexico, 64710
- Research Site
-
-
-
-
-
Moscow, Russian Federation, 115478
- Research Site
-
Moscow, Russian Federation, 143442
- Research Site
-
Saint Petersburg, Russian Federation, 199226
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 82445
- Research Site
-
Taichung, Taiwan, 40443
- Research Site
-
Taipei, Taiwan, 100
- Research Site
-
Taipei, Taiwan, 235
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei City, Taiwan, 114
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
New York
-
Commack, New York, United States, 11725
- Research Site
-
Harrison, New York, United States, 10604
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
New York, New York, United States, 10029
- Research Site
-
Uniondale, New York, United States, 11553
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Research Site
-
Germantown, Tennessee, United States, 38138
- Research Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patients must be at least 18 years of age
Male or female patients who have pathologically documented breast cancer that:
- Has a history of HER2-low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) with a validated assay
- Is documented as HR+ (either ER and/or PgR positive [ER or PgR ≥1%]) or ER and PgR negative (ER and PgR <1%) per ASCO/CAP guidelines in the metastatic setting
- Patient must have adequate tumor sample for biomarker assessment
- ECOG Performance Status of 0 or 1
For patients with HR+ disease:
Part 1: At least 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors), and at least 1 prior line of chemotherapy for MBC are required.
Part 2: Only 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors) for MBC is allowed. No prior chemotherapy in the metastatic setting is allowed. Note there are no patients with HR+ disease in Part 2 of Modules 2 and 3.
For patients with HR- disease:
Part 1: At least 1 prior line of chemotherapy for MBC is required. Note there are no patients with HR- disease in Part 1 of Modules 4 and 5.
Part 2: For Module 2, no prior lines of therapy for MBC are allowed, and for Modules 1 and 3, only 1 prior line of chemotherapy for MBC is allowed. Note there are no patients with HR- disease in Part 2 of Modules 4 and 5.
Key Exclusion Criteria:
- Uncontrolled intercurrent illness
- Uncontrolled or siginificant cardiovascular disease
- History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Lung-specific intercurrent clinically significant illnesses
- Has spinal cord compression or clinically active central nervous system metastases
- Active primary immunodeficiency
- Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
- Prior treatment with ADC that comprises of an exatecan derivative that is a topoisomerase I inhibitor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Module 1: T-DXd + capecitabine
T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
|
T-DXd: administered as an IV infusion
Other Names:
Capecitabine: administered orally
|
Experimental: Module 2: T-DXd + durvalumab + paclitaxel
T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
|
T-DXd: administered as an IV infusion
Other Names:
Durvalumab: administered as an IV infusion
Other Names:
Paclitaxel: administered as an IV infusion
Other Names:
|
Experimental: Module 3: T-DXd + capivasertib
T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
|
T-DXd: administered as an IV infusion
Other Names:
Capivasertib: administered orally
Other Names:
|
Experimental: Module 4: T-DXd + anastrozole
T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
|
T-DXd: administered as an IV infusion
Other Names:
Anastrozole: administered orally
Other Names:
|
Experimental: Module 5: T-DXd + fulvestrant
T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
|
T-DXd: administered as an IV infusion
Other Names:
Fulvestrant: administered as an IM injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events (AEs)- Part 1
Time Frame: Up to follow-up period, approximately 24 months
|
Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 24 months
|
Occurrence of serious adverse events (SAEs)- Part 1
Time Frame: Up to follow-up period, approximately 24 months
|
Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 24 months
|
Occurrence of adverse events (AEs)- Part 2
Time Frame: Up to follow-up period, approximately 24 months
|
Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 24 months
|
Occurrence of serious adverse events (SAEs)- Part 2
Time Frame: Up to follow-up period, approximately 24 months
|
Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)- Part 2
Time Frame: Until progression, assessed up to approximately 24 months
|
ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1
|
Until progression, assessed up to approximately 24 months
|
Progression Free Survival (PFS)- Part 2
Time Frame: Until progression or death, assessed up to approximately 24 months
|
PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause
|
Until progression or death, assessed up to approximately 24 months
|
Duration of Response (DoR)- Part 2
Time Frame: Until progression or death, assessed up to approximately 24 months
|
DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression
|
Until progression or death, assessed up to approximately 24 months
|
Overall Survival (OS)- Part 2
Time Frame: Until death, assessed up to approximately 24 months
|
OS defined as time from the date of first dose until the date of death by any cause
|
Until death, assessed up to approximately 24 months
|
Serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a
Time Frame: While on study drug up to study completion, approximately 24 months
|
Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration
|
While on study drug up to study completion, approximately 24 months
|
Immunogenicity of trastuzumab deruxtecan
Time Frame: Up to follow-up period, approximately 24 months
|
Percentage of patients who develop ADA for trastuzumab deruxtecan
|
Up to follow-up period, approximately 24 months
|
Serum Concentration of durvalumab
Time Frame: While on study drug up to study completion, approximately 24 months
|
Determination of durvalumab concentration in serum at different time points after administration
|
While on study drug up to study completion, approximately 24 months
|
Immunogenicity of durvalumab
Time Frame: Up to follow-up period, approximately 24 months
|
Percentage of patients who develop ADAs for durvalumab
|
Up to follow-up period, approximately 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Immunoconjugates
- Paclitaxel
- Trastuzumab
- Capecitabine
- Fulvestrant
- Durvalumab
- Anastrozole
- Trastuzumab deruxtecan
Other Study ID Numbers
- D967JC00002
- 2020-002797-27 (EudraCT Number)
- 2023-505690-33-00 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Trastuzumab deruxtecan
-
AstraZenecaDaiichi SankyoCompletedBreast CancerDenmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
-
Fudan UniversityNot yet recruitingTriple-Negative Breast CancerChina
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
MedSIRDaiichi Sankyo, Inc.Not yet recruitingBreast Cancer | Metastatic Breast Cancer
-
Daiichi Sankyo, Inc.AstraZenecaRecruiting
-
Cancer Trials IrelandRecruitingHER2-positive Breast CancerIreland
-
Fudan UniversityActive, not recruiting
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Medical University of ViennaDaiichi Sankyo, Inc.CompletedBreast Cancer Stage IVAustria
-
National Cancer Institute (NCI)SuspendedOsteosarcoma | Recurrent OsteosarcomaUnited States